View Older Stories

Aug 3, 2026 04:24PM Jazz Pharmaceuticals (JAZZ) Misses Q2 EPS by 47c; raises guidance

Jul 21, 2026 06:12AM Raymond James sees potential for beats across biopharma coverage

Jul 16, 2026 04:07PM Canaccord Starts Jazz Pharmaceuticals (JAZZ) at Buy

Jun 17, 2026 07:01AM Jazz Pharmaceuticals and AbCellera ink antibody research deal

Jun 16, 2026 04:06PM Jazz Pharmaceuticals presents Xywav sleep disorder data at SLEEP 2026 conference

Jun 10, 2026 05:22AM Jazz Pharmaceuticals (JAZZ) PT Raised to $307 at BofA Securities

Jun 9, 2026 09:27AM Bernstein SocGen Reiterates Market Perform Rating on Jazz Pharmaceuticals (JAZZ)

Jun 9, 2026 06:06AM Truist Securities Assumes Jazz Pharmaceuticals (JAZZ) at Buy

Jun 4, 2026 07:45AM Jazz Pharmaceuticals to present 21 abstracts at SLEEP 2026 conference

May 22, 2026 08:07AM Jazz Pharmaceuticals (JAZZ) PT Raised to $301 at Piper Sandler

May 21, 2026 04:38PM Bernstein SocGen Group Starts Jazz Pharmaceuticals (JAZZ) at Market Perform

May 19, 2026 04:14AM UBS Upgrades Jazz Pharmaceuticals (JAZZ) to Buy

May 6, 2026 05:24AM Jazz Pharmaceuticals (JAZZ) PT Raised to $258 at RBC Capital

May 5, 2026 04:31PM Jazz Pharmaceuticals (JAZZ) Tops Q1 EPS by 172c; offers guidance

Apr 30, 2026 01:31PM Jazz Pharmaceuticals (JAZZ) PT Raised to $232 at Jefferies

Apr 9, 2026 04:28PM Raymond James Starts Jazz Pharmaceuticals (JAZZ) at Outperform

Mar 19, 2026 08:32AM Jazz Pharmaceuticals (JAZZ) PT Raised to $232 at Piper Sandler

Mar 18, 2026 09:21AM RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'

Mar 9, 2026 04:01PM Barclays Reiterates Overweight Rating on Jazz Pharmaceuticals (JAZZ)

Feb 27, 2026 09:31AM Barclays Starts Jazz Pharmaceuticals (JAZZ) at Overweight (earlier)

Feb 24, 2026 04:14PM Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 25c

Jan 12, 2026 09:30AM Jazz Pharmaceuticals (JAZZ) PT Raised to $230 at Truist Securities

Jan 12, 2026 07:20AM Jazz Pharmaceuticals (JAZZ) PT Raised to $235 at Needham

Jan 12, 2026 07:06AM Boehringer Ingelheim partners with Jazz Pharmaceuticals on breast cancer study

Jan 9, 2026 04:57AM Jazz Pharmaceuticals (JAZZ) PT Raised to $263 at BofA Securities

Jan 8, 2026 04:07PM Jazz Pharmaceuticals names Thomas Riga as Chief Business Officer

Jan 8, 2026 08:49AM 4Q25/2026 Biotech Earnings Preview: RBC

Jan 7, 2026 04:13AM BofA on Jazz (JAZZ): 'We continue to see $1bn+ peak sales potential for zani in 1L GE'

Jan 6, 2026 02:18PM Baird's Brian Skorney on Jazz Pharmaceuticals (JAZZ): 'We are buyers on weakness'

Jan 6, 2026 01:33PM Jazz Pharmaceuticals reports positive Ziihera cancer trial results

Jan 6, 2026 11:46AM RBC on Jazz (JAZZ): 'Downside Move on HERIZON-GEA Data Leak Unwarranted - Zani Regimens Are Clearly Active and Will See Use'

Dec 10, 2025 07:30AM Jazz Pharmaceuticals (JAZZ) PT Raised to $219 at Piper Sandler

Dec 5, 2025 09:01AM Jazz Pharmaceuticals to present Epidiolex data at epilepsy conference

Nov 24, 2025 05:53AM UBS Downgrades Jazz Pharmaceuticals (JAZZ) to Neutral

Nov 18, 2025 05:00AM Jazz Pharmaceuticals (JAZZ) PT Raised to $235 at Wells Fargo

Nov 18, 2025 04:59AM Jazz Pharmaceuticals (JAZZ) PT Raised to $247 at BofA Securities

Nov 18, 2025 04:11AM Jazz Pharmaceuticals (JAZZ) PT Raised to $209 at Baird

Nov 17, 2025 11:04AM Jazz Pharmaceuticals (JAZZ) PT Raised to $194 at RBC Capital

Nov 12, 2025 05:00AM Werewolf Therapeutics' (HOWL) an 'Attractive Investment Opportunity'- Citizens

Nov 11, 2025 07:45AM Jazz Pharmaceuticals presents Modeyso data at neuro-oncology meeting

Nov 5, 2025 04:33PM Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by $2.20, provides guidance

Oct 22, 2025 03:19PM RBC Capital on Jazz Pharmaceuticals (JAZZ): 'we would be buyers on the potential upcoming positive ph.III zanidatimab data in GEA'

Oct 3, 2025 08:05AM Stifel Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)

Oct 2, 2025 03:33PM FDA approves lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-TAJS for extensive-stage small cell lung cancer

Sep 23, 2025 04:04PM Jazz Pharmaceuticals (JAZZ) PT Raised to $167 at Morgan Stanley

Sep 22, 2025 07:45AM Jazz Pharmaceuticals presents Xywav data at medical conferences

Sep 15, 2025 08:29AM Piper Sandler Reiterates Overweight Rating on Jazz Pharmaceuticals (JAZZ)

Sep 11, 2025 08:18AM RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'

Sep 9, 2025 07:45AM Jazz Pharmaceuticals' Modeyso added to NCCN cancer guidelines

Aug 28, 2025 09:25AM Jazz Pharmaceuticals (JAZZ) PT Raised to $205 at Truist Securities

View Older Stories